Renaptys Vaccines, LLC Developing a propriatary Stable Peptide Immunogen (SPI) platform
SPIs represent a new class of synthetic vaccines that are more effective and will be less expensive to manufacture, store, and ship than vaccines currently on the market.
Our lead candidate, REN-1005P, is a computationally designed synthetic "universal" vaccine against the influenza virus (pandemic and seasonal). REN-1005P is the most advanced synthetic antigen able to stimulate a meaningful humoral response against the HA stalk on the influenza virus (including H1,H2,H3,H5 and H7 strains)
Our lead candidate, REN-1005P, is a computationally designed synthetic "universal" vaccine against the influenza virus (pandemic and seasonal). REN-1005P is the most advanced synthetic antigen able to stimulate a meaningful humoral response against the HA stalk on the influenza virus (including H1,H2,H3,H5 and H7 strains)